What changed from existing technology?
This study looked at how a protein called endothelial lipase relates to inflammation and oxidative stress in people with heart disease who take statins. It found that the levels of this protein didn't change much between people with different levels of heart disease.
The study provides new insights into the relationship between endothelial lipase and coronary artery disease in patients taking statins, suggesting that EL levels may not be directly linked to disease severity.
Commercialization signals visible at publication
This is not a success probability or investment opinion. It prioritizes follow-up using evidence available when the paper was published.
Verified evidence · 1
mmatory and oxidative stress markers in statin-treated patients with coronary artery disease: association with angiographic severity. Endothelial lipase (EL)
Title ↗- 시제품·장치 구현 근거 미확인
- 제조·규모 확장 근거 미확인
Later patent, company, clinical, and production events are added separately only after verification.
Patent check: Not checked yetCurrent technology stage: Near commercialization
See what changed before reading the full paper.
What still needs to be solved?
Repeated real-world validation, manufacturability, cost, and long-term stability still require follow-up evidence.
What could change if this succeeds?
The findings suggest that serum endothelial lipase levels may not be a useful biomarker for assessing the severity of coronary artery disease in patients taking statins.
Keep following this technology
Revisit changes when new papers, patents, company participation, validation, or products appear.